CRDF
HEALTHCARECardiff Oncology Inc
AI Insight
What's Moving CRDF Today?
No stock-specific AI insight has been generated for CRDF yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.16$4.56
$1.26
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.67
Dividend Yield—
Dividend / Share—
ROE-84.8%
Profit Margin—
Debt / Equity—
Trading
Volume974K
Avg Volume (10D)—
Shares Outstanding68.4M
CRDF News
21 articles- CRDF: Phase II Update; Survival Advantage ExtendedYahoo Finance·Jun 22, 2026
- Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual MeetingYahoo Finance·Jun 2, 2026
- Kazia Therapeutics Appoints James Levine as Chief Financial OfficerYahoo Finance·Jun 2, 2026
- Cardiff Oncology to Participate in the Jefferies Global Healthcare ConferenceYahoo Finance·Jun 1, 2026
- CRDF: First Quarter 2026 ResultsYahoo Finance·May 22, 2026
- Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCYahoo Finance·May 21, 2026
- Cardiff Oncology And 2 Other Promising Penny Stocks For Your WatchlistYahoo Finance·May 20, 2026
- [8-K] Cardiff Oncology, Inc. Reports Material EventStock Titan·May 20, 2026
- Cardiff Oncology Reports First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 14, 2026
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 28, 2026
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent ActivityYahoo Finance·Apr 27, 2026
- Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026GlobeNewswire Inc.·Apr 21, 2026
- Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual MeetingYahoo Finance·Apr 17, 2026
- Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of GrowthYahoo Finance·Apr 9, 2026
- CRDF: Colorectal Cancer KOL EventYahoo Finance·Apr 6, 2026
- Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC WebinarMarketbeat·Mar 25, 2026
- Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal CancerYahoo Finance·Mar 20, 2026
- Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual MeetingYahoo Finance·Mar 19, 2026
- CRDF: 10-K Filing Prompts Model UpdateYahoo Finance·Mar 2, 2026
- Cardiff Oncology to Participate in Three Upcoming Investor ConferencesYahoo Finance·Feb 26, 2026
- Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRCMarketbeat·Feb 26, 2026
All 21 articles loaded
Price Data
Open$1.26
Previous Close$1.25
Day High$1.32
Day Low$1.24
52 Week High$4.56
52 Week Low$1.16
52-Week Range
$1.16$4.56
$1.26
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.67
Dividend Yield—
Dividend / Share—
ROE-84.8%
Profit Margin—
Debt / Equity—
Trading
Volume974K
Avg Volume (10D)—
Shares Outstanding68.4M
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—